JP2013536408A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536408A5
JP2013536408A5 JP2013518767A JP2013518767A JP2013536408A5 JP 2013536408 A5 JP2013536408 A5 JP 2013536408A5 JP 2013518767 A JP2013518767 A JP 2013518767A JP 2013518767 A JP2013518767 A JP 2013518767A JP 2013536408 A5 JP2013536408 A5 JP 2013536408A5
Authority
JP
Japan
Prior art keywords
composition
maximum threshold
less
item
statin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518767A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536408A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042846 external-priority patent/WO2012003475A1/en
Publication of JP2013536408A publication Critical patent/JP2013536408A/ja
Publication of JP2013536408A5 publication Critical patent/JP2013536408A5/ja
Pending legal-status Critical Current

Links

JP2013518767A 2010-07-02 2011-07-01 ガレクチン−３測定によりモニタリングされるスタチン療法 Pending JP2013536408A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36121610P 2010-07-02 2010-07-02
US61/361,216 2010-07-02
PCT/US2011/042846 WO2012003475A1 (en) 2010-07-02 2011-07-01 Statin therapy monitored by galectin- 3 measurement

Publications (2)

Publication Number Publication Date
JP2013536408A JP2013536408A (ja) 2013-09-19
JP2013536408A5 true JP2013536408A5 (enExample) 2014-08-07

Family

ID=44628757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518767A Pending JP2013536408A (ja) 2010-07-02 2011-07-01 ガレクチン−３測定によりモニタリングされるスタチン療法

Country Status (4)

Country Link
US (1) US20120029003A1 (enExample)
EP (1) EP2588111A1 (enExample)
JP (1) JP2013536408A (enExample)
WO (1) WO2012003475A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0919975A2 (pt) * 2008-10-29 2015-12-15 Bg Medicine Inc imunoensaio para galectina-3
EA201270316A1 (ru) 2009-08-25 2012-09-28 БиДжи МЕДИСИН, ИНК. Галектин-3 и сердечная ресинхронизирующая терапия
WO2013169890A1 (en) * 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
EP2843414B1 (en) * 2013-08-26 2018-09-19 Roche Diagniostics GmbH Marker for statin treatment stratification in heart failure
ES2712201T3 (es) 2014-01-28 2019-05-09 Hoffmann La Roche Biomarcadores para la evaluación de riesgos y la monitorización del tratamiento en pacientes de insuficiencia cardíaca que han recibido terapia guiada por el péptido natriurético de tipo B
AU2022388722A1 (en) * 2021-11-09 2024-05-23 Truebinding, Inc. Methods of treating or inhibiting cardiovascular diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4632901A (en) 1984-05-11 1986-12-30 Hybritech Incorporated Method and apparatus for immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
EP0988552B1 (en) 1997-06-10 2010-11-24 Lpath, Inc. Methods for early detection of heart disease
WO2004111654A2 (en) * 2003-06-06 2004-12-23 Ciphergen Biosystems, Inc. Serum biomarkers in ischaemic heart disease
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
DK1718967T3 (da) * 2004-02-03 2013-06-03 Diadexus Inc Metoder til at detektere Lp-PLA2 aktivitet
US9934294B2 (en) 2014-09-26 2018-04-03 Wal-Mart Stores, Inc. System and method for using past or external information for future search results

Similar Documents

Publication Publication Date Title
S Antonopoulos et al. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials
Blum et al. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis
JP2017528427A5 (enExample)
JP2016517883A5 (enExample)
IL292829B2 (en) Fixed dose combinations comprising etc1002 and one or more statins for treating or reducing cardiovascular risk
JP2018508551A5 (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
Grover et al. The pleotropic role of statins: Could it be the imminent host modulation agent in periodontics?
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
RU2018133690A (ru) Лечение пациентов с гомозиготной семейной гиперхолестеринемией, получающих липидоснижающую терапию
Rogers et al. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin
JP2012505905A5 (enExample)
Stein Management of dyslipidemia in the high-risk patient
JP2016529505A5 (enExample)
JP2010505866A5 (enExample)
JP4839309B2 (ja) 血栓症治療剤
Tan et al. Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience
RU2003113328A (ru) Профилактическое и терапевтическое средство для лечения осложнений, связанных с диабетом
MX2013007310A (es) Gemcabeno y derivados para tratar la pancreatitis.
Kückelhaus et al. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis
Mason Update on statins
Auer et al. Lessons learned from statin trials
B Alonzo Myths and facts concerning the use of statins in very old patients
CA2798707A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
Pedersen Intensive lipid-lowering therapy for patients with aortic stenosis
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤